Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2‐Mutant Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1067
Abstract: Mutant isocitrate dehydrogenase 1/2 (mIDH1/2) proteins catalyze production of the oncometabolite D‐2‐hydroxyglutarate (2‐HG). Ivosidenib and enasidenib are oral inhibitors of mIDH1 and mIDH2, respectively. An open‐label phase 1 study is evaluating the safety and efficacy… read more here.
Keywords: combined intensive; ivosidenib enasidenib; enasidenib combined; intensive induction ... See more keywords
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Haematology"
DOI: 10.1111/ejh.13649
Abstract: While most patients with mantle cell lymphoma (MCL) receive therapy shortly after diagnosis, a subset of patients with indolent‐behaving disease can safely defer treatment. In this subgroup, we evaluated the importance of treatment intensity in… read more here.
Keywords: intensive induction; mantle cell; initial therapy; cell lymphoma ... See more keywords
Azacitidine to Consolidate and Deepen the Therapeutic Response Achieved by Intensive Induction Treatment in a Young Patient Affected by NPM1mut-AML Who Has Become Ineligible for High-Dose Consolidation
Sign Up to like & getrecommendations! Published in 2022 at "Chemotherapy"
DOI: 10.1159/000520205
Abstract: Acute myeloid leukemia (AML) is the most common leukemia in adults. In spite of the most recent discoveries about the molecular landscape of this disease, the treatment of elderly and unfit young patients continues to… read more here.
Keywords: intensive induction; young patient; induction treatment; npm1mut aml ... See more keywords
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
Sign Up to like & getrecommendations! Published in 2024 at "Blood Advances"
DOI: 10.1182/bloodadvances.2024012858
Abstract: Key Points • OS of patients aged ≥60 years with NPM1-mutant AML was similar with IC vs HMA/VEN after adjustment for clinicopathologic characteristics.• Patients with normal cytogenetics and without a concurrent FLT3 internal tandem duplication… read more here.
Keywords: hypomethylating agents; induction chemotherapy; intensive induction; mutant aml ... See more keywords
Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0706
Abstract: Aim: This retrospective, observational study assessed healthcare resource utilization (HCRU) and costs for newly diagnosed acute myeloid leukemia (AML) patients receiving intensive induction chemotherapy. Materials & methods: Adult AML patients with inpatient hospitalization or hospital-based outpatient… read more here.
Keywords: induction chemotherapy; receiving intensive; newly diagnosed; intensive induction ... See more keywords